IKZF1 Antibodies

Structure of IKZF1

IKZF1 is a zinc finger transcription factor protein with a molecular weight of approximately 57-60 kDa. Its precise molecular weight may fluctuate slightly due to alternative splicing of different isomers.

This protein is encoded by multiple exons. Its N-terminal is the transcriptional activation domain, and the C-terminal contains a continuous zinc finger structure (where the 1st to 4th fingers are responsible for recognizing specific DNA sequences, and the 5th to 6th fingers mediate dimerization). Proteins bind to gene regulatory regions through their zinc finger structures to form homologous or heterodimers to regulate the transcription of target genes, playing a core role in lymphocyte development.

Fig. 1 Structure and mutation spectrum of IKZF1 in AML.¹

Key structural properties of IKZF1:

• Contains multiple C2H2 type zinc finger domains in series
• DNA sequence recognition and binding are carried out using specific zinc fingers
• Protein dimerization is mediated by the C-terminal zinc finger
• Independently of n-terminal domain transcription activation/inhibition function

Functions of IKZF1

The main function of IKZF1 is to regulate lymphocyte development as a transcription factor. In addition, it is also involved in various physiological and pathological processes such as tumor suppression and cell cycle regulation.

Unlike general-purpose transcription factors with wide-ranging effects, IKZF1 precisely regulates immune-related genes by recognizing specific DNA sequences and forming dimers, which demonstrates its high specificity in the hematopoietic system.

Applications of IKZF1 and IKZF1 Antibody in Literature

1. Eckardt, Jan-Niklas, et al. "Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia." Leukemia 37.12 (2023): 2395-2403. https://doi.org/10.1038/s41375-023-02061-1

The article indicates that in a study of 1,606 patients with acute myeloid leukemia (AML), mutations in the IKZF1 gene (especially the N159S hotspot) coexisted with abnormalities such as RUNX1 and GATA2, leading to anemia and thrombocytopenia. Multivariate analysis confirmed that IKZF1 mutation is an independent adverse prognostic factor, significantly reducing the response rate and survival rate, and affecting the transplantation efficacy, suggesting that it should be included in the AML risk stratification model.

2. Paolino, Jonathan, et al. "IKZF1 alterations and therapeutic targeting in B-cell acute lymphoblastic leukemia." Biomedicines 12.1 (2024): 89. https://doi.org/10.3390/biomedicines12010089

The article indicates that the IKAROS protein encoded by the IKZF1 gene is a key factor in lymphocyte development. Its absence in B-cell acute lymphocytic leukemia can lead to functional loss, endowing cancer cells with the ability to self-renew, and is significantly associated with treatment resistance and poor prognosis. Identifying this mutation is helpful for intensifying treatment and improving the therapeutic effect of high-risk patients.

3. Feng, Lin, Hang Zhang, and Ting Liu. "Multifaceted roles of IKZF1 gene, perspectives from bench to bedside." Frontiers in Oncology 14 (2024): 1383419. https://doi.org/10.3389/fonc.2024.1383419

The article indicates that the IKAROS protein encoded by the IKZF1 gene is a key transcription factor regulating lymphocyte generation and immunity. Its dysfunction is not only related to immunodeficiency diseases, but also plays an important role in the transformation of leukemia. IKZF1 mutation is an independent adverse prognostic marker for B-cell acute lymphocytic leukemia and has been used for clinical risk stratification to guide treatment.

4. Garcia-Solorio, Joaquin, et al. "IKZF1plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemia." Frontiers in Oncology 14 (2024): 1337954. https://doi.org/10.3389/fonc.2024.1337954

Studies have found that among children with B-ALL in Mexico, the mutation rate of the IKZF1 gene is as high as 35.9%. The IKZF1plus feature formed by its coexistence with PAX5, CDKN2A/2B, etc. accounts for 21.8%, which is significantly higher than previous reports. This feature is associated with advanced age, high-risk stratification and a decline in overall survival rate, highlighting the importance of incorporating it into routine genomic testing for improving prognosis.

5. Wang, Yang, et al. "Identification of IKZF1 genetic mutations as new molecular subtypes in acute myeloid leukaemia." Clinical and Translational Medicine 13.6 (2023): e1309. https://doi.org/10.1002/ctm2.1309

This study focuses on the rare IKZF1 mutation in acute myeloid leukemia. Research has found that IKZF1 N159S is a hotspot mutation in AML. By reshaping the transcription factor binding spectrum, it leads to high expression of HOXA/B and unique immune characteristics, thereby defining a novel molecular subpopulation with a unique pathogenic mechanism in AML.

Creative Biolabs: IKZF1 Antibodies for Research

Creative Biolabs specializes in the production of high-quality IKZF1 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom IKZF1 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our IKZF1 antibodies, custom preparations, or technical support, contact us at email.